Jonathan Edwards
Senior Member (Voting Rights)
This post and two following have been copied from this thread:
Concerns about craniocervical instability surgery in ME/CFS
______________________________
The trouble with 'objective' is that it has layers of meaning. Placebos probably do not alter things like haemoglobin or CRP level. However, although going back to work is 'objective' in one sense it is not the same sense and I think we have to accept that, as in the rituximab trial, people got well enough to get back to work having had a treatment that has no effect in itself. That may be a 'placebo effect' in the broad sense of all the reasons why people get better that are not specifically due to a treatment but it may also be in the narrower sense. We just do not know.
Having worked in clinical trials for years and rituximab specifically I think I can be pretty sure, having looked at the Norwegian results, that the drug has no effect. The reasons are complex and they are not just about the lack of any difference in the two phase 3 groups. The detailed dynamics of the open phase 2 trial makes it pretty clear that the apparent benefits from treatment were spurious. The apparent effects in the open phase 2 were not just in a tiny subgroup that might not have shown up in phase 3. The idea that a subgroup benefits doesn't fit.
Concerns about craniocervical instability surgery in ME/CFS
______________________________
I'm v tired so can't reply properly but will say this:
We've had a discussion on this forum about placebo and it seemed like most of us were fairly sceptical about the ability of a placebo to change objective outcomes.
https://s4me.info/threads/is-there-...f-placebo-improving-objective-outcomes.11251/
Re rituximab, some people reckon it just helps a subset of patients.
The trouble with 'objective' is that it has layers of meaning. Placebos probably do not alter things like haemoglobin or CRP level. However, although going back to work is 'objective' in one sense it is not the same sense and I think we have to accept that, as in the rituximab trial, people got well enough to get back to work having had a treatment that has no effect in itself. That may be a 'placebo effect' in the broad sense of all the reasons why people get better that are not specifically due to a treatment but it may also be in the narrower sense. We just do not know.
Having worked in clinical trials for years and rituximab specifically I think I can be pretty sure, having looked at the Norwegian results, that the drug has no effect. The reasons are complex and they are not just about the lack of any difference in the two phase 3 groups. The detailed dynamics of the open phase 2 trial makes it pretty clear that the apparent benefits from treatment were spurious. The apparent effects in the open phase 2 were not just in a tiny subgroup that might not have shown up in phase 3. The idea that a subgroup benefits doesn't fit.
Last edited by a moderator: